MyoKardia — Technical Presentation (July 2016)
10 slides from MyoKardia's technical presentation, Jul 11, 2016
Slide 1: Data Supplement to Press Release: MyoKardia Announces Topline Clinical Data for MYK-461
Data Supplement to Press Release July 11, 2016 MyoKardia Announces Topline Clinical Data Supporting Advancement of MYK-461 to Phase 2 PIONEER-HCM Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients Exhibit 99.2
Slide 2: Safe-Harbor and Forward Looking Statements
Safe-Harbor and Forward Looking Statements Statements in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are usuall
Slide 3: Hypertrophic Cardiomyopathy: Devastating Disease with No Approved Therapies
Hypertrophic Cardiomyopathy: Devastating Disease with No Approved Therapies Disease Burden Standard of Care Chronic, progressive heart failure Can be debilitating and shorten life Shortness of breath, chest pain, fatigue can interfere with quality of life Increased risk of stroke and sudden cardiac
Slide 4: Symptomatic Obstructive HCM: Our PIONEER-HCM Study Population
Symptomatic Obstructive HCM: Our PIONEER-HCM Study Population Physiological complication of HCM; thickened muscle obstructs LV outflow tract Defined as ≥30 mmHg pressure gradient across LVOT; severe obstruction (≥50 mmHg) is primary eligibility criterion for invasive interventions Earlier onset of s
Slide 5: Phase 1 Trials MYK-461-001, -002 and -003 Design
MYK-461-001 MYK-461-002 MYK-461-003 Single Ascending Dose (SAD) Trial in HCM Patients SAD Trial in Healthy Volunteers Multiple Ascending Dose (MAD) Trial in Healthy Volunteers Trial Design Open-label, sequential-group, SAD study Randomized, double-blind, placebo-controlled, sequential-group SAD stud
Slide 6: Favorable Safety Profile Demonstrated in HCM Patients and Healthy Volunteers
Favorable Safety Profile Demonstrated in HCM Patients and Healthy Volunteers HCM Patients Following administration of MYK-461, all Adverse Events (AEs) reported, except one, were mild to moderate(1) One Serious Adverse Event (SAE) reported Occurred in the highest dose cohort (144 mg) Transient episo
Slide 7: Clinical Proof of Mechanism: Dose-Dependent PD Response Measured by Independent Biomarkers of Contractility
Clinical Proof of Mechanism: Dose-Dependent PD Response Measured by Independent Biomarkers of Contractility SAD Results: Response at 2 Hours NOTE: Data represent mean ± SEM.
Slide 8: LVOT Gradient Reduced in Two Patients Following a Single Dose of MYK-461
Two subjects enrolled in 001 study had a history of obstruction, and displayed a provocable LVOT pressure gradient Each patient administered single 96 mg dose of MYK-461 Both patients displayed reductions in contractility, as measured by three independent biomarkers LVOT Gradient Reduced in Two Pati
Slide 9: Repeated Daily Dosing Also Demonstrates Clinical Proof of Mechanism
Repeated Daily Dosing Also Demonstrates Clinical Proof of Mechanism MAD Results in Healthy Volunteers: Response at Day 25 NOTE: Data represent mean ± SEM.
Slide 10: Summary and Next Steps: Advancing to Phase 2 (PIONEER-HCM)
Summary Phase 1 Program 86 healthy volunteers and 15 HCM patients dosed with MYK-461 across three Phase 1 studies Safety Favorable safety profile observed across a meaningful dose range, including multiple doses up to 28 days Pharmacokinetics (PK) PK profile well documented for single and multiple d